JP2014521744A5 - - Google Patents

Download PDF

Info

Publication number
JP2014521744A5
JP2014521744A5 JP2014526078A JP2014526078A JP2014521744A5 JP 2014521744 A5 JP2014521744 A5 JP 2014521744A5 JP 2014526078 A JP2014526078 A JP 2014526078A JP 2014526078 A JP2014526078 A JP 2014526078A JP 2014521744 A5 JP2014521744 A5 JP 2014521744A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
cycloalkyl
alkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014526078A
Other languages
English (en)
Japanese (ja)
Other versions
JP5903162B2 (ja
JP2014521744A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/050051 external-priority patent/WO2013025424A1/en
Publication of JP2014521744A publication Critical patent/JP2014521744A/ja
Publication of JP2014521744A5 publication Critical patent/JP2014521744A5/ja
Application granted granted Critical
Publication of JP5903162B2 publication Critical patent/JP5903162B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014526078A 2011-08-17 2012-08-09 糖尿病の治療に有用な新規1,2,3,4−テトラヒドロキノリン誘導体 Expired - Fee Related JP5903162B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161524462P 2011-08-17 2011-08-17
US61/524,462 2011-08-17
PCT/US2012/050051 WO2013025424A1 (en) 2011-08-17 2012-08-09 A Novel 1,2,3,4-Tetrahydroquinoline Derivative Useful for the Treatment of Diabetes

Publications (3)

Publication Number Publication Date
JP2014521744A JP2014521744A (ja) 2014-08-28
JP2014521744A5 true JP2014521744A5 (enExample) 2015-09-24
JP5903162B2 JP5903162B2 (ja) 2016-04-13

Family

ID=46690732

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014526078A Expired - Fee Related JP5903162B2 (ja) 2011-08-17 2012-08-09 糖尿病の治療に有用な新規1,2,3,4−テトラヒドロキノリン誘導体

Country Status (30)

Country Link
US (1) US8431706B2 (enExample)
EP (1) EP2744806B1 (enExample)
JP (1) JP5903162B2 (enExample)
KR (1) KR101570624B1 (enExample)
CN (1) CN103687856B (enExample)
AP (1) AP3589A (enExample)
AR (1) AR087451A1 (enExample)
AU (1) AU2012295372A1 (enExample)
BR (1) BR112014003079A2 (enExample)
CA (1) CA2843474C (enExample)
CL (1) CL2014000357A1 (enExample)
CO (1) CO6880069A2 (enExample)
CR (1) CR20140052A (enExample)
DO (1) DOP2014000018A (enExample)
EA (1) EA022165B1 (enExample)
EC (1) ECSP14013211A (enExample)
ES (1) ES2578165T3 (enExample)
GT (1) GT201400022A (enExample)
IL (1) IL230635A (enExample)
IN (1) IN2014MN00191A (enExample)
MA (1) MA35351B1 (enExample)
MX (1) MX2014001832A (enExample)
PE (1) PE20140831A1 (enExample)
PH (1) PH12014500366A1 (enExample)
SG (1) SG11201401793PA (enExample)
TN (1) TN2014000058A1 (enExample)
TW (1) TWI537262B (enExample)
UA (1) UA110983C2 (enExample)
WO (1) WO2013025424A1 (enExample)
ZA (1) ZA201400705B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105722841A (zh) 2013-11-14 2016-06-29 卡迪拉保健有限公司 新型杂环化合物
WO2015084692A1 (en) 2013-12-04 2015-06-11 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
US10059667B2 (en) 2014-02-06 2018-08-28 Merck Sharp & Dohme Corp. Antidiabetic compounds
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
CN109666027A (zh) * 2017-10-17 2019-04-23 中国科学院上海药物研究所 一类酰胺结构的gpr40激动剂化合物及其用途
DK3737470T5 (da) 2018-01-08 2024-05-27 Celon Pharma Sa 3-phenyl-4-hexynsyrederivater som gpr40-agonister
WO2019160882A1 (en) 2018-02-13 2019-08-22 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
KR102591947B1 (ko) 2018-04-19 2023-10-25 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
PE20210642A1 (es) 2018-07-13 2021-03-23 Gilead Sciences Inc Inhibidores de pd-1/pd-l1
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
EP3978485B1 (en) 2019-05-31 2026-02-11 Hyundai Pharm Co., Ltd. Novel crystal form of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative
TWI751585B (zh) * 2019-06-28 2022-01-01 美商美國禮來大藥廠 類升糖素肽1受體促效劑
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ,インク. Gpr119アゴニスト
EP4052790A4 (en) * 2019-10-31 2023-12-27 China Petroleum & Chemical Corporation SUPPORTED CATALYST, PRODUCTION PROCESS THEREOF AND APPLICATION THEREOF
MX2022010548A (es) 2020-02-28 2022-09-23 Kallyope Inc Agonistas de gpr40.
MX2022014505A (es) 2020-05-19 2022-12-13 Kallyope Inc Activadores de la ampk.
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
KR102699076B1 (ko) * 2021-04-01 2024-08-27 현대약품 주식회사 3-(4-(벤질옥시)페닐)헥스-4-이노익산 유도체의 신규 용도
CN115317484B (zh) * 2022-08-26 2023-07-18 北京箭牧科技有限公司 Ly2922470在制备预防或治疗脑血管疾病或组织缺血再灌注损伤药物中的应用
CN115671105B (zh) * 2022-11-22 2023-10-27 北京箭牧科技有限公司 Ly2922470在制备预防或治疗肾脏疾病药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT199900147A (es) * 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
JP2004529132A (ja) * 2001-03-27 2004-09-24 アクテリオン ファマシューティカルズ リミテッド 1,2,3,4−テトラヒドロイソキノリン誘導体
EP1737809B1 (en) 2004-02-27 2013-09-18 Amgen, Inc Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
WO2005087710A1 (ja) * 2004-03-15 2005-09-22 Takeda Pharmaceutical Company Limited アミノフェニルプロパン酸誘導体
JP4859665B2 (ja) * 2004-03-30 2012-01-25 武田薬品工業株式会社 アルコキシフェニルプロパン酸誘導体
AR078522A1 (es) * 2009-10-15 2011-11-16 Lilly Co Eli Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
AR078948A1 (es) 2009-11-30 2011-12-14 Lilly Co Eli Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes

Similar Documents

Publication Publication Date Title
JP2015512931A5 (enExample)
JP2013542218A5 (enExample)
JP2014515013A5 (enExample)
JP2011500550A5 (enExample)
JP2013032389A5 (enExample)
JP2012533546A5 (enExample)
JP2012506896A5 (enExample)
JP2013508347A5 (enExample)
JP2010524932A5 (enExample)
JP2015505296A5 (enExample)
JP2013534248A5 (enExample)
JP2013512277A5 (enExample)
JP2010521516A5 (enExample)
JP2011246469A5 (enExample)
JP2013532130A5 (enExample)
JP2011088926A5 (enExample)
JP2010132677A5 (enExample)
PE20140831A1 (es) Nuevo derivado de 1,2,3,4-tetrahidroquinolina util para el tratamiento de diabetes
JP2011046708A5 (enExample)
JP2008517020A5 (enExample)
JP2017511368A5 (enExample)
JP2009501745A5 (enExample)
JP2011016798A5 (enExample)
JP2012511558A5 (enExample)
JP2010510263A5 (enExample)